- Home
- VSTM vs PBYI Comparison
VSTM vs PBYI Comparison
Compare VSTM & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- PBYI
- Stock Information
- Founded
- VSTM 2010
- PBYI 2010
- Country
- VSTM United States
- PBYI United States
- Employees
- VSTM N/A
- PBYI N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- PBYI Health Care
- Exchange
- VSTM Nasdaq
- PBYI Nasdaq
- Market Cap
- VSTM 132.0M
- PBYI 126.5M
- IPO Year
- VSTM 2012
- PBYI N/A
- Fundamental
- Price
- VSTM $4.00
- PBYI $2.98
- Analyst Decision
- VSTM Strong Buy
- PBYI Strong Buy
- Analyst Count
- VSTM 8
- PBYI 1
- Target Price
- VSTM $14.57
- PBYI $7.00
- AVG Volume (30 Days)
- VSTM 950.0K
- PBYI 557.7K
- Earning Date
- VSTM 11-06-2024
- PBYI 11-07-2024
- Dividend Yield
- VSTM N/A
- PBYI N/A
- EPS Growth
- VSTM N/A
- PBYI 492.79
- EPS
- VSTM N/A
- PBYI 0.47
- Revenue
- VSTM $10,000,000.00
- PBYI $243,569,000.00
- Revenue This Year
- VSTM N/A
- PBYI N/A
- Revenue Next Year
- VSTM $108.05
- PBYI N/A
- P/E Ratio
- VSTM N/A
- PBYI $6.06
- Revenue Growth
- VSTM N/A
- PBYI 6.30
- 52 Week Low
- VSTM $2.10
- PBYI $2.23
- 52 Week High
- VSTM $14.22
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- VSTM 54.40
- PBYI 49.25
- Support Level
- VSTM $3.71
- PBYI $2.32
- Resistance Level
- VSTM $4.29
- PBYI $3.25
- Average True Range (ATR)
- VSTM 0.33
- PBYI 0.31
- MACD
- VSTM -0.05
- PBYI -0.03
- Stochastic Oscillator
- VSTM 31.82
- PBYI 42.86
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.